Severance Hospital Yonsei University Health System

Seoul, South Korea

50 recruiting

Showing 120 of 73 trials

Recruiting
Phase 1

A Study of BG-C477 in Participants With Advanced Solid Tumors

Advanced Solid Tumors
BeOne Medicines310 enrolled54 locationsNCT06596473
Recruiting
Phase 3

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC220 enrolled112 locationsNCT06919965
Recruiting
Phase 3

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Carcinoma, Squamous Cell
Johnson & Johnson Enterprise Innovation Inc.500 enrolled193 locationsNCT04892173
Recruiting
Phase 2

Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis
Contineum Therapeutics324 enrolled53 locationsNCT07284459
Recruiting
Phase 2Phase 3

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

Crohn Disease
Janssen Research & Development, LLC1,092 enrolled368 locationsNCT07196722
Recruiting
Phase 3

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

Colitis Ulcerative
Janssen Research & Development, LLC882 enrolled400 locationsNCT07196748
Recruiting
Phase 2

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma
Janssen Research & Development, LLC157 enrolled71 locationsNCT07266441
Recruiting
Phase 3

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Colorectal Neoplasms
Janssen Research & Development, LLC1,000 enrolled238 locationsNCT06662786
Recruiting
Phase 1Phase 2

A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC60 enrolled13 locationsNCT07227025
Recruiting
Phase 3

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Colorectal Neoplasms
Janssen Research & Development, LLC700 enrolled250 locationsNCT06750094
Recruiting
Phase 3

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC500 enrolled198 locationsNCT07276399
Recruiting
Phase 3

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Neoplasms
Janssen Research & Development, LLC1,203 enrolled172 locationsNCT07164443
Recruiting
Phase 3

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

Colitis UlcerativeArthritis, PsoriaticCrohns Disease+1 more
Janssen Research & Development, LLC196 enrolled49 locationsNCT06663332
Recruiting
Phase 3

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Metastatic Colorectal Cancer
Amgen450 enrolled291 locationsNCT06252649
Recruiting
Phase 3

A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works

Paroxysmal nocturnal hemoglobinuria
Regeneron Pharmaceuticals202 enrolled46 locationsNCT05744921
Recruiting
Phase 3

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant
Janssen Research & Development, LLC800 enrolled150 locationsNCT07225946
Recruiting
Phase 1

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Metastatic Hepatocellular CarcinomaLocal Advanced Hepatocellular CarcinomaAlpha-fetoprotein (AFP)-Producing Gastric Cancer+2 more
BeOne Medicines392 enrolled48 locationsNCT06427941
Recruiting
Phase 3

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines630 enrolled192 locationsNCT06943872
Recruiting
Phase 3

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Myasthenia Gravis
Janssen Research & Development, LLC199 enrolled112 locationsNCT04951622
Recruiting
Phase 3

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer
Amgen750 enrolled144 locationsNCT07213674